iBio Expands Pipeline with Bispecific Antibody for PH-HFpEF
Event summary
- iBio to host conference call on March 17, 2026, to discuss its cardiopulmonary program targeting PH-HFpEF.
- Company's bispecific antibody aims to block Activin A, GDF8 (myostatin), and GDF11 to reduce cardiac fibrosis and reverse pulmonary vascular remodeling.
- iBio expects to declare the optimized bispecific antibody development candidate for PH-HFpEF in Q3 2026.
- HFpEF affects millions worldwide and is closely associated with obesity, diabetes, hypertension, and aging.
The big picture
iBio's strategic pivot into PH-HFpEF reflects a broader industry trend of targeting complex cardiometabolic diseases with innovative biopharmaceuticals. The company's bispecific antibody approach aims to address multiple core drivers of PH-HFpEF biology simultaneously, a gap in currently approved therapies. This expansion positions iBio to compete in a high-need market with significant growth potential.
What we're watching
- Development Timeline
- Whether iBio can meet its target of declaring the optimized bispecific antibody development candidate for PH-HFpEF in Q3 2026.
- Market Potential
- The pace at which iBio can address the substantial unmet need in the HFpEF market, which affects millions worldwide.
- Strategic Vision
- How iBio's long-term vision to build a family of therapies targeting core cardiometabolic pathways will impact its market position.
Related topics